Want to see CTXR full AI Analyst Report?
Top Page
Citius Pharmaceuticals
(NASDAQ:CTXR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.59
▲(13.08% Upside)
Action:Reiterated
Date:08/22/26
The score is held down primarily by weak financial fundamentals (large operating losses and sustained cash burn despite early revenue) and a generally bearish longer-term technical backdrop. Corporate events add both upside (LYMPHIR launch traction and supportive clinical signals) and a meaningful risk (Nasdaq minimum bid-price compliance), while valuation metrics provide limited support due to a negative P/E and no stated dividend yield.
Positive Factors
LYMPHIR Commercial Traction
Rapid growth in ordering sites and vial volumes, alongside broad payer coverage, indicates improving commercial adoption. A wider institutional footprint can support recurring demand and strengthen LYMPHIR's market position over the next several quarters.
Negative Factors
Persistent Cash Burn
The business is not yet self-financing and continues to consume substantial cash to fund operations and development. Unless commercialization expands materially or costs decline, ongoing burn may increase dependence on external financing and constrain strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
LYMPHIR Commercial Traction
Rapid growth in ordering sites and vial volumes, alongside broad payer coverage, indicates improving commercial adoption. A wider institutional footprint can support recurring demand and strengthen LYMPHIR's market position over the next several quarters.
Read all positive factors
Citius Pharmaceuticals (CTXR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.57M
Dividend YieldN/A
Average Volume (3M)285.32K
Price to Earnings (P/E)―
Beta (1Y)2.82
Revenue GrowthN/A
EPS Growth57.48%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.11
Shares Outstanding27,452,570
10 Day Avg. Volume442,850
30 Day Avg. Volume285,317
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside669.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.87
Revenue Forecast (FY)$20.84M
Citius Pharmaceuticals Business Overview & Revenue Model
Company Description
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cance...
How the Company Makes Money
null...
Citius Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.42M | -214.25K | -209.61K | 0.00 | 0.00 | -164.87K |
| EBITDA | -57.17M | -38.20M | -38.64M | -36.54M | -33.14M | -23.37M |
| Net Income | -46.27M | -37.43M | -39.14M | -32.54M | -33.64M | -23.05M |
Balance Sheet | ||||||
| Total Assets | 142.26M | 130.94M | 116.65M | 103.61M | 114.00M | 142.43M |
| Cash, Cash Equivalents and Short-Term Investments | 17.01M | 4.25M | 3.25M | 26.48M | 41.71M | 70.07M |
| Total Debt | 7.18M | 1.81M | 262.87K | 481.25K | 678.23K | 855.47K |
| Total Liabilities | 66.35M | 53.41M | 42.55M | 12.18M | 10.57M | 9.65M |
| Stockholders Equity | 66.61M | 67.55M | 70.08M | 90.83M | 102.83M | 132.18M |
Cash Flow | ||||||
| Free Cash Flow | -34.87M | -26.55M | -28.20M | -29.06M | -28.36M | -64.26M |
| Operating Cash Flow | -34.87M | -26.55M | -28.20M | -29.06M | -28.36M | -24.25M |
| Investing Cash Flow | -12.75M | -5.75M | -5.00M | 0.00 | 0.00 | -40.01M |
| Financing Cash Flow | 58.54M | 33.30M | 9.97M | 13.83M | 0.00 | 120.47M |
Citius Pharmaceuticals Technical Analysis
Negative
0.52
Price Trends
0.59
Negative
0.64
Negative
0.78
Negative
Market Momentum
<0.01
Positive
46.66
Neutral
15.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.59, and below the 200-day MA of 0.78, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.66 is Neutral, neither overbought nor oversold. The STOCH value of 15.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTXR.
Citius Pharmaceuticals Risk Analysis
Citius Pharmaceuticals disclosed 59 risk factors in its most recent earnings report. Citius Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.19M | -1.31 | -47.86% | ― | -93.71% | 23.89% | |
47 Neutral | $18.45M | -2.25 | -5515.09% | ― | 3581.22% | 98.63% | |
46 Neutral | $16.57M | -0.27 | -67.42% | ― | ― | 57.48% | |
45 Neutral | $17.73M | -1.15 | -66.69% | ― | -62.70% | -121.27% | |
42 Neutral | $15.90M | -0.95 | 763.44% | ― | ― | ― | |
42 Neutral | $15.88M | -0.01 | -1335.64% | ― | ― | 78.25% |
* Healthcare Sector Average
CTXR
Citius Pharmaceuticals
0.58
-0.82
-58.79%
BLRX
Bioline RX Ltd Sponsored ADR
2.70
-0.95
-26.03%
PTN
Palatin Technologies
10.47
0.26
2.55%
DARE
Daré Bioscience
0.75
-1.27
-62.87%
LPCN
Lipocine
2.15
-0.83
-27.85%
KALA
KALA BIO
0.82
-528.68
-99.85%
Citius Pharmaceuticals Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Citius Pharmaceuticals Receives Nasdaq Extension to Regain Compliance
Negative
Aug 21, 2026
On August 17, 2026, Citius Pharmaceuticals disclosed that Nasdaq granted the company an extension until February 8, 2027, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The com...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Citius Oncology reports strong LYMPHIR U.S. launch momentum
Positive
Aug 5, 2026
On August 5, 2026, Citius Oncology reported strong commercial momentum for LYMPHIR’s U.S. launch, highlighting rapid uptake among treatment centers and wholesalers. The number of new institutions ordering LYMPHIR rose 78% quarter over quarte...
Business Operations and StrategyProduct-Related Announcements
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers
Positive
Jun 1, 2026
On June 1, 2026, Citius Oncology reported Phase 1 data from an investigator-initiated study of LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in recurrent or refractory gynecologic malignancies, presented May 30, 2026 at the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.